Furthermore, cemiplimab has the same safety and clinical benefits as other PD-1 inhibitors in patients with metastatic or recurrent cervical cancer who are resistant to the combination chemotherapy (platinum and taxane). Here, PDCD1 is linked to cervical carcinoma.